PGNY Stock Forecast 2025-2026
Distance to PGNY Price Targets
PGNY Price Momentum
10 Quality Stocks Worth Considering Now
Researching Progyny (PGNY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PGNY and similar high-potential opportunities.
Latest PGNY Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, PGNY has a neutral consensus with a median price target of $26.00 (ranging from $23.00 to $34.00). Currently trading at $22.31, the median forecast implies a 16.5% upside. This outlook is supported by 3 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stephanie Davis at SVB Leerink, projecting a 52.4% upside. Conversely, the most conservative target is provided by Richard Close at Canaccord Genuity, suggesting a 3.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGNY Analyst Ratings
PGNY Price Target Range
Latest PGNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $23.00 |
| Feb 11, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $25.00 |
| Jan 28, 2025 | JP Morgan | Anne Samuel | Neutral | Maintains | $23.00 |
| Dec 2, 2024 | JP Morgan | Anne Samuel | Neutral | Downgrade | $17.00 |
| Nov 14, 2024 | Barclays | Sarah James | Overweight | Maintains | $17.00 |
| Nov 13, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $17.00 |
| Nov 13, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $21.00 |
| Nov 13, 2024 | Truist Securities | Jailendra Singh | Hold | Downgrade | $19.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $25.00 |
| Sep 20, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $18.00 |
| Sep 19, 2024 | Jefferies | Glen Santangelo | Buy | Maintains | $24.00 |
| Sep 19, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $25.00 |
| Sep 19, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $26.00 |
| Sep 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $22.00 |
| Sep 19, 2024 | JMP Securities | Constantine Davides | Market Perform | Downgrade | $0.00 |
| Sep 19, 2024 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $21.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $37.00 |
| Aug 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $31.00 |
| Aug 7, 2024 | Leerink Partners | Michael Cherny | Market Perform | Downgrade | $25.00 |
| Aug 7, 2024 | BTIG | David Larsen | Neutral | Downgrade | $0.00 |
Progyny Inc. (PGNY) Competitors
The following stocks are similar to Progyny based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Progyny Inc. (PGNY) Financial Data
Progyny Inc. has a market capitalization of $1.91B with a P/E ratio of 39.1x. The company generates $1.17B in trailing twelve-month revenue with a 4.7% profit margin.
Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of +5.3% and return on equity of +11.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Progyny Inc. (PGNY) Business Model
About Progyny Inc.
Provides fertility benefits management solutions.
Progyny Inc. operates by partnering with large employers to deliver comprehensive fertility and family-building benefits. The company generates revenue by offering a managed approach to fertility care that is integrated into employer health plans, thus helping companies optimize healthcare spending while enhancing employee satisfaction.
Progyny addresses the increasing demand for fertility treatments through advanced, technology-driven services, including IVF and donor services. The company plays a crucial role in the intersection of healthcare and corporate wellness, positioning itself as a key player in the employee benefits landscape.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
675
CEO
Mr. Peter Anevski CPA
Country
United States
IPO Year
2019
Website
www.progyny.comProgyny Inc. (PGNY) Latest News & Analysis
A new program offers comprehensive support for working parents and caregivers, focusing on return-to-work challenges, emotional health, and benefits navigation.
The program's focus on supporting working parents and caregivers could enhance employee retention and productivity, positively impacting company performance and stock value.
Progyny, Inc. (Nasdaq: PGNY) will participate in investor conferences on March 10 and 11, 2025, including a fireside chat at the Leerink Partners Global Healthcare Conference.
Progyny's participation in major investor conferences signals potential growth and transparency, attracting attention from investors looking for insights into the company's future performance.
Progyny CEO Pete Anevski indicates the company is well-positioned for the year despite healthcare challenges, anticipating new client acquisition and retention of existing customers.
Progyny's CEO signals confidence in growth despite healthcare challenges, suggesting potential for client acquisition and retention, which may lead to stable revenue and stock performance.
Progyny Tops EPS Forecast, Eyes Growth
27 days agoProgyny (PGNY) reported fourth-quarter earnings on February 27, with revenue and adjusted EPS exceeding analysts' expectations.
Progyny's Q4 earnings beat forecasts, indicating strong demand for its fertility benefits. This performance can enhance investor confidence and potentially drive stock value higher.
Progyny, Inc. will hold its Q4 2024 Earnings Conference Call on February 27, 2025, at 4:45 PM ET, featuring key executives and analysts from various firms.
Progyny's Q4 earnings call may reveal key financial performance metrics and strategic insights, influencing stock valuation and investor sentiment.
The company reported Q3 revenue of $298.4 million, up 10.6%, and generated $52.2 million in operating cash flow. It also issued financial guidance for 2025, marking ten years of revenue growth.
Quarterly revenue growth and strong cash flow indicate solid business performance, while consistent revenue growth signals stability and potential for future investment returns.
Frequently Asked Questions About PGNY Stock
What is Progyny Inc.'s (PGNY) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Progyny Inc. (PGNY) has a median price target of $26.00. The highest price target is $34.00 and the lowest is $23.00.
Is PGNY stock a good investment in 2025?
According to current analyst ratings, PGNY has 3 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PGNY stock?
Wall Street analysts predict PGNY stock could reach $26.00 in the next 12 months. This represents a 16.5% increase from the current price of $22.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Progyny Inc.'s business model?
Progyny Inc. operates by partnering with large employers to deliver comprehensive fertility and family-building benefits. The company generates revenue by offering a managed approach to fertility care that is integrated into employer health plans, thus helping companies optimize healthcare spending while enhancing employee satisfaction.
What is the highest forecasted price for PGNY Progyny Inc.?
The highest price target for PGNY is $34.00 from Stephanie Davis at SVB Leerink, which represents a 52.4% increase from the current price of $22.31.
What is the lowest forecasted price for PGNY Progyny Inc.?
The lowest price target for PGNY is $23.00 from Richard Close at Canaccord Genuity, which represents a 3.1% increase from the current price of $22.31.
What is the overall PGNY consensus from analysts for Progyny Inc.?
The overall analyst consensus for PGNY is neutral. Out of 11 Wall Street analysts, 3 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $26.00.
How accurate are PGNY stock price projections?
Stock price projections, including those for Progyny Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
